A per-pack price, and the pack is the whole fact
Nothing here is a monthly rate. Each figure buys a stated quantity: a two-pack of pens, a four-pack of single-dose pens, a single prefilled pen, or a count of tablets. Thirteen of the seventy-three sellers here carry at least one figure that is not a monthly rate, and on this row every figure is one.
How long a pack lasts depends on the dose, and the pharmacy does not say. That is not evasion — it is what a pharmacy price is — but it does mean a reader has to do the division themselves, and the answer changes as the dose climbs.
The tablet route is the exception to the guesswork, because the page prints a full six-rung quantity ladder from one month's tablets up to a year's. The per-tablet rate is not flat across it, so the largest quantity is not simply twelve times the smallest.
The product spec is on screen and not in the text
The form, the strength and the quantity render inside form controls rather than as ordinary text. A reader sees them plainly, at a normal size, beside the price. Anything reading the page as text sees a price with no product attached, which on a per-quantity pharmacy price is the entire meaning.
Every spec on this row was read from the control's own value with a real laid-out rectangle, not from the page text. That is recorded because it changes what a figure quoted from this site is worth: a price lifted from here without its pack size is not a price at all.
The product pages themselves are reached from the pharmacy's own medication index, which carries no dollar figure of its own. A reader who stops at the index will conclude there are no prices here.
A liraglutide price, which is genuinely scarce
Five of the seventy-three sellers here publish a liraglutide price of any kind, and only three of those publish a compounded one. This row adds a brand liraglutide figure with the pack and strength stated, which is the version of that molecule a reader is least likely to find priced anywhere.
Thirteen of the seventy-three sellers here publish brand-name prices and no compounded price at all, and this is one of them. Everything sold is an FDA-approved finished drug, dispensed by a licensed pharmacy that says so and prints its certifications.
Two tirzepatide brands appear on the pharmacy's own medication index with no priced page linked from it. Those figures are unknown rather than unavailable, and this row does not treat their absence from the index as an absence from the pharmacy.
No company named, and no governing law
The footer identifies a trademark owner and nothing else. There is no operating company, no phrase naming who runs the business, and no dispute-resolution clause naming a state. A census of the full terms found no choice of law, no forum and no state name, alongside an arbitration clause and a class-action waiver that do exist.
That is not unique here — several sellers on this roster publish no governing-law state — but the combination is unusual for a pharmacy, which is a licensed business with a physical address and printed certifications. The address and the certifications are published; the company is not.
Twenty of the seventy-three sellers here say nothing either way about a membership or programme fee, and this is one of them. What the terms do say about money is narrower: insurance is not accepted for mail-order prescriptions, and the buyer is responsible for applicable charges and taxes.
Two statements about where it ships, and they disagree
The product pages carry a trust strip promising free shipping to all fifty states. The terms say the service is available in the United States and its territories, and that the pharmacy may not offer services in certain states and territories where it is not permitted.
Both are live, both are the seller's own, and neither withdraws the other. This row records the empty list rather than resolving the conflict by arithmetic, and both sentences are in its cons.
Forty-one of the seventy-three sellers here publish no service area at all, so an empty field is ordinary. What is not ordinary is publishing two answers. Confirm your state directly before planning around either sentence.
Marley Drug's published pricing
| Medication | Price | Verified |
|---|---|---|
| Liraglutide (brand) | $1,015A cash price for one pack, not for a month: Form "Prefilled Pens (2 Pack)", Strength "6mg/mL", Quantity "1", with Shipping "Free" beside it, and "Requires Prescription" and "In stock" on the same card. How long a two-pack lasts depends on the dose, and the pharmacy does not say. | September 2026source |
| Semaglutide (brand) | $1,600A cash price for one pack of four single-dose pens at the top maintenance strength: Form "Single Dose Prefilled Pens (4 Pack)", Strength "2.4mg/0.75mL", Quantity "1", Shipping "Free". Four weekly pens is the usual month at this strength, but the page states a pack and not a period. | September 2026source |
| Semaglutide (brand) | $1,200A cash price for a single prefilled pen: Form "Prefilled Injection Pen", Strength "0.25mg or 0.5mg", Quantity "1", Shipping "Free". One pen covers a different number of weeks at each of the two strengths the selector offers together, and the page does not separate them. | September 2026source |
| Semaglutide (brand) | $1,070.81The bottom of a six-rung quantity ladder the page prints in full: "$1070.81 for 30 tablets, $2001.62 for 60 tablets, $2872.43 for 90 tablets, $5484.85 for 180 tablets, $8097.28 for 270 tablets, $10709.71 for 360 tablets", Form "Tablet", Strength "3mg". A count of tablets, not a period — and the per-tablet rate is not flat across the ladder. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 73 providers reviewed here are paid partners today; the other 69 are not. See how this works.
See Marley Drug's current price →Good fit if
- Buyers filling a brand GLP-1 prescription at a pharmacy and paying cash, who want the pack size and strength printed beside the figure.
- Anyone looking for a published liraglutide price, which is scarce across this whole comparison.
- Readers who want a full quantity ladder for the tablet route rather than a single starting figure.
- People who want the dispensing party to be unambiguous, because here the seller is the pharmacy.
Look elsewhere if
- Anyone who wants a monthly figure. Every price here is a pack, and the pharmacy does not say how long a pack lasts.
- Readers who want a compounded route or a cheaper preparation. There is none here.
- Buyers who need a named operating company or a governing-law state before they transact.
- People who need their state confirmed. Two published statements disagree about where this pharmacy will ship.
- Anyone expecting to use insurance, which the terms say is not accepted for mail-order prescriptions.
How this review was verified
- Read every product page in a browser after plain requests to this host returned a bot challenge at every depth, including for the two control paths. A challenge is a block, not an absence, and nothing was recorded from those responses.
- Read the form, strength and quantity from each control's own value rather than from the page text, because these specs render inside form controls and never appear in the text a reader-as-text would see.
- Took every product URL from the pharmacy's own medication index rather than minting one, and recorded that the index itself carries no dollar figure.
- Recorded each figure as a pack price with the pack named in the qualifier, and set every row's period so that no template prints a monthly suffix beside a quantity price.
- Censused the full terms for a governing-law clause, a forum, and a state name, and found none; the arbitration clause and class-action waiver that do exist are recorded instead.
- Recorded both of the seller's own statements about where it ships, verbatim and unreconciled, rather than choosing the one that made a cleaner field.
- Recorded the two tirzepatide brands named on the index with no priced page as unread rather than as unpriced.
- Searched the agency's published warning-letter record for both the trading name and the trademark owner, 2017 to 2026, and read every returned row: none names this company. That search covers warning letters only; untitled letters are published separately and were not searched.